Related Experiment Videos
[Postischemic dysfunction and persistent ischemia in the early postinfarction period. Evaluation by
P Rosselli1, A Garfagnini, F Bianchi
1Servizio di Cardiologia e Unità-USL 4-Lavagna, GE.
Giornale Italiano Di Cardiologia
|February 1, 1996
Summary
The Echo-dobutamine-atropine stress test (ECHO-DOB) effectively assesses post-infarction dysfunction and ischemia. This test helps identify patients at risk for adverse events, guiding therapeutic decisions.
Area of Science:
- Cardiology
- Diagnostic Imaging
- Nuclear Cardiology
Background:
- Early post-myocardial infarction (MI) management requires accurate assessment of myocardial viability and ischemia.
- Persistent ischemia and post-ischemic dysfunction significantly impact patient prognosis after acute MI.
- Non-invasive imaging modalities are crucial for evaluating myocardial function and perfusion post-MI.
Purpose of the Study:
- To evaluate the utility of the Echo-dobutamine-atropine stress test (ECHO-DOB) in assessing post-ischemic dysfunction and persistent ischemia in the early post-infarction period.
- To determine the correlation between ECHO-DOB findings and coronary angiography results.
- To identify patients at risk for adverse cardiac events based on early post-MI assessment.
Main Methods:
- A study involving 138 patients (age ≤75 years) with their first uncomplicated acute myocardial infarction (AMI) treated with thrombolysis.
- ECHO-DOB performed within two weeks of AMI onset, with low doses assessing viability and high doses assessing ischemia under echocardiographic and ECG monitoring.
- Wall Motion Score Index (WMSI) used for semi-quantitative analysis; coronary angiography performed in 82.3% of patients within 30 days.
Main Results:
- Low-dose Dobutamine (DOB) improved contractile dysfunction in 67.6% of patients, indicating viable myocardium in 31.5%.
- High-dose DOB worsened contractile dysfunction in 47% of patients, with 62.5% showing previously detected viability (viable but ischemic myocardium).
- ECHO-DOB demonstrated a sensitivity of 69% for viable myocardium and 78% for ischemia, with specificities of 77% and 100%, respectively. No major adverse events were reported.
Conclusions:
- The ECHO-DOB test is valuable for assessing functional significance post-MI, correlating with coronary angiography findings.
- This test aids in identifying patients at higher risk for adverse events.
- Integrating ECHO-DOB with angiographic data can optimize therapeutic and surgical management strategies.